Phase 1 Clinical Trial of A Novel CDK Inhibitor Dinaciclib (SCH 727965) in Combination With Bortezomib and Dexamethasone in Relapsed Multiple Myeloma
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 14 Dec 2017
At a glance
- Drugs Bortezomib (Primary) ; Bortezomib (Primary) ; Dexamethasone (Primary) ; Dinaciclib (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- 26 Jan 2017 Status changed from suspended to active, no longer recruiting.
- 22 Jul 2016 Status changed from recruiting to suspended.
- 18 Jul 2016 Status changed from suspended to recruiting.